Clinical Trial Update: Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of ranibizumab for subfoveal choroidal neovascularization due to age-related macular degeneration. Results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (Lucentis) (ranibizumab)

Snippet

Sponsor: Novartis | Conditions: Age Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2011-03-16